Maturity onset diabetes of the young (MODY) constitutes a few percent of this disease, with HNF1A- and GCK-MODY being its most common forms. We examined the impact on QoL (Quality of Life) of monogenic diabetes among patients with HNF1A-MODY or GCK mutation carrier status and compared it to type 1 diabetic (T1DM) individuals.
Methods: The study included 80 patients with HNF1A-MODY and 89 GCK gene mutation carriers (45 patients with diabetes and 44 prediabetic). We also examined 128 T1DM patients as a control group. Diabetes-specific QoL was assessed using the Audit of Diabetes Dependent Quality of Life questionnaire.
Results: Both HNF1A-MODY and GCK-MODY groups had similar mean age (41.7 vs. 38.0 years, respectively) and BMI (24.1 vs. 24.3 kg/m2), whereas T1DM patients were younger (34.2 years) with similar BMI (25.0 kg/m2). Less than a third of GCK mutation carriers were on pharmacotherapy (31%), while the majority of HNF1A mutationcarriersused oral drugs or insulin (82.5%) (p<0.0001).While QoL were similar in three groups (p=0.66), both the impact of diabetes on the patient’s QoL andthe average weighted impact (AWI) differed between three groups (p<0.001; p<0.001, respectively). For MODY patients, both indices were larger in HNF1A-MODY patients than in GCK-MODY (-0.96 ± 1.vs. -0.63 ± 0.88, p>0.and -1.52 ± 1.44 vs. -0.95±1.06, p=0.01, respectively). However, the largest impact of diabetes on the patient’s QoL andAWI were observed in the T1DM patients (-1.6 ± 1.05; -1.99 ± 1.39, respectively). The highest impact of diabetes (>-1.5) was observed in all groups on ^‘freedom to eat‘, ‘feelings about future‘, and ‘freedom to drink‘. In the HNF1A-MODY group, all three major indices of QoL were more affected for patients on insulin as compared to the other individuals.
Conclusions:Diagnosis of the most frequent subtypes of MODY has a negative impact on QoL for affected individuals, although, it is smaller than in T1DM. Mode of treatment seems to influence QoL for HNF1A-MODY subjects.
M. Szopa: None.
